KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Short term Debt (2016)

Vertex Pharmaceuticals has reported Short term Debt over the past 6 years, most recently at $300.0 million for Q4 2016.

  • Quarterly results put Short term Debt at $300.0 million for Q4 2016, up 320.78% from a year ago — trailing twelve months through Dec 2016 was $300.0 million (up 320.78% YoY), and the annual figure for FY2016 was $300.0 million, up 320.78%.
  • Short term Debt for Q4 2016 was $300.0 million at Vertex Pharmaceuticals, up from $297.8 million in the prior quarter.
  • Over the last five years, Short term Debt for VRTX hit a ceiling of $300.0 million in Q4 2016 and a floor of $14.2 million in Q4 2014.
  • Median Short term Debt over the past 3 years was $108.8 million (2015), compared with a mean of $140.3 million.
  • Peak annual rise in Short term Debt hit 416.82% in 2016, while the deepest fall reached 320.78% in 2016.
  • Vertex Pharmaceuticals' Short term Debt stood at $14.2 million in 2014, then skyrocketed by 401.87% to $71.3 million in 2015, then surged by 320.78% to $300.0 million in 2016.
  • The last three reported values for Short term Debt were $300.0 million (Q4 2016), $297.8 million (Q3 2016), and $221.6 million (Q2 2016) per Business Quant data.